US-based DexCom has published positive results for the continuous glucose monitoring (CGM) study (DiaMonD) conducted in diabetes patients on multiple daily injections (MDI) insulin therapy.

DIaMonD is a randomised, controlled study performed at 24 endocrinology practices in the US to evaluate the effect of CGM on A1C and hypoglycemia in participants on MDI insulin regimen.

The data, which was published in the Journal of the American Medical Association (JAMA) on 24 January, indicated that Dexcom CGM system users on MDI have observed a 1% average A1C decrease after 24 weeks of regular use, compared to baseline.

"The positive outcomes in the 60+ population will be critical to our efforts in driving CGM coverage for Medicare-eligible patients."

It was also found that CGM users spent more time in target range (70mg to 180mg/dL) and less in hypoglycemia and hyperglycemia, when compared to standard glucose monitoring metre users.

Dexcom president and chief executive officer Kevin Sayer said: "We are delighted that the Dexcom CGM System was able to demonstrate significant benefits among a diverse group of patients, but more importantly, the positive outcomes in the 60+ population will be critical to our efforts in driving CGM coverage for Medicare-eligible patients."

The study was conducted in 158 participants with type one diabetes on MDI and involved usage of Dexcom G4 Platinum CGM System with Software 505.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A subset of subjects with an A1C greater than 8.5% have experienced a 1.3% decrease in A1C from baseline at week 24.

CGM users have also observed a decrease in hypoglycemia during the night with only 0.6% time spent in hypoglycemia compared to 2.9% at baseline, while the time spent in hyperglycemia was also less.

Based on the observed A1C reductions in participants of various education levels, math ability and age, the study also established that CGM is easy to use.